Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation
| Autor: | Joya Singh, Mikhail de Jesus, Suresh J. Antony, Jessalyn Lance |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty ARDS 030106 microbiology Disease Infectious and parasitic diseases RC109-216 medicine.disease_cause Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Tocilizumab Internal medicine medicine 030212 general & internal medicine Liver transplant Coronavirus business.industry COVID-19 medicine.disease Pneumonia Renal transplant Infectious Diseases chemistry Respiratory failure Solid organ business Cytokine storm |
| Zdroj: | IDCases IDCases, Vol 21, Iss, Pp e00888-(2020) |
| ISSN: | 2214-2509 |
| DOI: | 10.1016/j.idcr.2020.e00888 |
| Popis: | As of May 14, 2020, the World Health Organization has reported approximately 4.3 million cases of the novel Coronavirus Disease (COVID-19) with approximately 294,046 deaths worldwide [1]. Solid organ transplant recipients who are on chronic immunosuppressants fall within a special population of COVID-19 patients since they are more susceptible to complications secondary to COVID-19. Currently, we do not have data on treating COVID-19 patients with solid organ transplants with tocilizumab, an interleukin-6 (IL-6) inhibitor. We report a case of COVID-19 in a patient with a kidney and liver transplant and discuss the early use of tocilizumab to prevent the cytokine storm and attempt to reduce the likelihood of progression to Acute Respiratory Distress Syndrome (ARDS). In addition, we present other COVID-19 related transplant cases reported in the literature outlining the presenting clinical signs and outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|